Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 - Nature

Primary accessions

Gene Expression Omnibus

Data deposits

Data have been deposited at GEO under accession number GSE25706 (methylation status of each CpG site (beta value) can be found in Supplementary Table 3).

• 09 December 2010

  A panel was replaced in Fig. 1c and data accession information was added.

1. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009)

   Article  ADS  CAS  Google Scholar 

2. Iyer, L. M., Tahiliani, M., Rao, A. & Aravind, L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8, 1698–1710 (2009)

   Article  CAS  Google Scholar 

3. Viguié, F. et al. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19, 1411–1415 (2005)

   Article  Google Scholar 

4. Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144–147 (2009)

   Article  CAS  Google Scholar 

5. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009)

   Article  Google Scholar 

6. Jankowska, A. M. et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113, 6403–6410 (2009)

   Article  CAS  Google Scholar 

7. Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nature Genet. 41, 838–842 (2009)

   Article  CAS  Google Scholar 

8. Levine, R. L. & Carroll, M. A common genetic mechanism in malignant bone marrow diseases. N. Engl. J. Med. 360, 2355–2357 (2009)

   Article  CAS  Google Scholar 

9. Mullighan, C. G. TET2 mutations in myelodysplasia and myeloid malignancies. Nature Genet. 41, 766–767 (2009)

   Article  CAS  Google Scholar 

10. Tefferi, A. et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 23, 900–904 (2009)

    Article  CAS  Google Scholar 

11. Tefferi, A. et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 23, 1343–1345 (2009)

    Article  CAS  Google Scholar 

12. Tefferi, A. et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 23, 905–911 (2009)

    Article  CAS  Google Scholar 

13. Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010)

    Article  ADS  CAS  Google Scholar 

14. Hayatsu, H. & Shiragami, M. Reaction of bisulfite with the 5-hydroxymethyl group in pyrimidines and in phage DNAs. Biochemistry 18, 632–637 (1979)

    Article  CAS  Google Scholar 

15. Huang, Y. et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS ONE 5, e8888 (2010)

    Article  ADS  Google Scholar 

16. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315–322 (2009)

    Article  ADS  CAS  Google Scholar 

17. Tefferi, A. Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Leuk. Lymphoma 49, 2231–2232 (2008)

    Article  Google Scholar 

18. Smith, L. T., Otterson, G. A. & Plass, C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 23, 449–456 (2007)

    Article  CAS  Google Scholar 

19. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008)

    Article  CAS  Google Scholar 

20. Gal-Yam, E. N., Saito, Y., Egger, G. & Jones, P. A. Cancer epigenetics: modifications, screening, and therapy. Annu. Rev. Med. 59, 267–280 (2008)

    Article  CAS  Google Scholar 

21. Ehrlich, M. DNA hypomethylation in cancer cells. Epigenomics 1, 239–259 (2009)

    Article  CAS  Google Scholar 

22. Lengauer, C. Cancer. An unstable liaison. Science 300, 442–443 (2003)

    Article  CAS  Google Scholar 

23. Bröske, A.-M. et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nature Genet. 41, 1207–1215 (2009)

    Article  Google Scholar 

24. Gaudet, F. et al. Induction of tumors in mice by genomic hypomethylation. Science 300, 489–492 (2003)

    Article  ADS  CAS  Google Scholar 

25. Walsh, C. P., Chaillet, J. R. & Bestor, T. H. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nature Genet. 20, 116–117 (1998)

    Article  CAS  Google Scholar 

26. Jiang, Y. et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113, 1315–1325 (2009)

    Article  CAS  Google Scholar 

Download references

Author notes

1. Myunggon Ko, Yun Huang, Jungeun An & Anjana Rao

   Present address: Present address: La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA (M.K., Y.H., J.A., A.R.).,

2. Myunggon Ko and Yun Huang: These authors contributed equally to this work.

Authors and Affiliations

1. Department of Pathology, Harvard Medical School, Immune Disease Institute and Program in Cellular and Molecular Medicine, Children’s Hospital Boston, Boston, 02115, Massachusetts, USA

   Myunggon Ko, Yun Huang, Utz J. Pape, Mamta Tahiliani, Hozefa S. Bandukwala, Jungeun An, Edward D. Lamperti, Kian Peng Koh & Anjana Rao

2. Department of Translational Hematology and Oncology Research, and Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, 44195, Ohio, USA

   Anna M. Jankowska, Rebecca Ganetzky & Jaroslaw P. Maciejewski

3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, 02115, Massachusetts, USA

   Utz J. Pape & X. Shirley Liu

4. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, 20894, Maryland, USA

   L. Aravind

5. Division of Pediatric Hematology/Oncology, Children's Hospital Boston and Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Boston, 02115, Massachusetts, USA

   Suneet Agarwal

Contributions

M.K. analysed the biochemical effects of patient-associated TET2 mutations and performed the in vitro differentiation studies; Y.H. generated and characterized the anti-CMS antiserum, developed the quantitative dot-blot assay and quantified 5hmC in DNA samples from patients and healthy controls. A.M.J., R.G. and J.P.M. provided patient and control DNA for 5hmC quantification, performed DNA methylation arrays and analysed TET2 mutational status in patients. U.J.P. and X.S.L. carried out the statistical analysis of 5hmC levels and methylation data; M.T., H.S.B. and K.P.K. provided critical reagents; J.A. and E.D.L. contributed to molecular cloning and mouse maintenance respectively; and L.A. and S.A. provided essential intellectual input. A.R. set overall goals, coordinated collaborations and wrote the manuscript.

Corresponding authors

Correspondence to Jaroslaw P. Maciejewski or Anjana Rao.

Competing interests

The authors declare no competing financial interests.

Cite this article

Ko, M., Huang, Y., Jankowska, A. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010). https://doi.org/10.1038/nature09586

Download citation

• Received: 29 March 2010

• Revised: 19 October 2010

• Accepted: 07 November 2010

• Published: 09 December 2010

• Issue Date: 09 December 2010

• DOI: https://doi.org/10.1038/nature09586